Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reactive hypoglycemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Reactive hypoglycemia. Displaying page 1 of 1.
    EudraCT Number: 2018-001067-23 Sponsor Protocol Number: PasHypo Start Date*: 2018-05-07
    Sponsor Name:Zealand University Hospital
    Full Title: Pasireotide in the treatment of hypoglycemia following gastric bypass surgery
    Medical condition: Postprandial reactive hypoglycemia in patients with prior Roux-en-Y gastric bypass surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10059038 Postprandial hypoglycemia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001086-50 Sponsor Protocol Number: HypoGB2015 Start Date*: 2015-06-03
    Sponsor Name:Køge Sygehus
    Full Title: Treatment of hypoglycemia following gastric bypass surgery
    Medical condition: Postprandial reactive hypoglycemia in patients with prior Roux-en-Y gastric bypass surgery.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10059038 Postprandial hypoglycemia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000667-74 Sponsor Protocol Number: CV006 Start Date*: 2021-11-30
    Sponsor Name:Medisch Centrum Leeuwarden BV
    Full Title: The effect of bile acid binding with colesevelam on postprandial glucose concentrations in patients after RYGB and cholecystectomy : a meal test study
    Medical condition: Post Bariatric Hypoglycemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10059038 Postprandial hypoglycemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005554-20 Sponsor Protocol Number: NL51854.091.14 Start Date*: 2015-08-06
    Sponsor Name:Radboud University Medical Center Nijmegen
    Full Title: Visualizing beta cells in patients with postprandial hyperinsulinemic hypoglycemia after bariatric surgery
    Medical condition: Hyperinsulinaemic hypoglycaemia after Roux-en-Y gastric bypass surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10059035 Postprandial hypoglycaemia LLT
    18.0 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    18.0 10027433 - Metabolism and nutrition disorders 10060378 Hyperinsulinaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005241-16 Sponsor Protocol Number: CKN-DASI120-RYGB Start Date*: 2021-03-19
    Sponsor Name:Center for Clinical Metabolic Research at Herlev-Gentofte Hospital
    Full Title: Ready-to-use dasiglucagon for the treatment of postprandial hypoglycaemia in Roux-en-Y gastric bypass operated patients
    Medical condition: Postprandial hyperinsulinemic hypoglycaemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10079748 Reactive hypoglycaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000756-17 Sponsor Protocol Number: S61145 Start Date*: 2018-05-30
    Sponsor Name:KU Leuven
    Full Title: Impact of Tight blood Glucose Control within normal fasting ranges with insulin titration prescribed by the Leuven algorithm in adult critically ill patients
    Medical condition: Hyperglycemia in critically ill patients (stress hyperglycemia)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10042216 Stress induced hyperglycemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004216-70 Sponsor Protocol Number: BM17864 Start Date*: 2007-01-30
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, parallel group, placebo-controlled (with open-label active comparator arm), dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004421-28 Sponsor Protocol Number: A2171084 Start Date*: 2006-11-09
    Sponsor Name:
    Full Title: A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIE...
    Medical condition: Diabetes Mellitus type II (not insulin independent)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) SE (Completed) FR (Completed) BE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-002836-97 Sponsor Protocol Number: 240193 Start Date*: 2012-12-20
    Sponsor Name:Tartu University Hospital
    Full Title: Pharmacokinetics of penicillin, ampicillin and gentamicin in near- term and full-term neonates
    Medical condition: neonatal sepsis, pneumonia and meningitis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002800-16 Sponsor Protocol Number: C3591024 Start Date*: 2019-12-10
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANT...
    Medical condition: Infections with suspected or confirmed Gram-negative pathogens
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10032531 Other specified bacterial infections in conditions classified elsewhere and of unspecified site LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) EE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000497-80 Sponsor Protocol Number: H7U-MC-IDAV Start Date*: 2007-07-27
    Sponsor Name:Eli Lilly and Company Ltd
    Full Title: A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabete...
    Medical condition: Male or female nonsmoking patients 18 years of age or older who have had type 1 diabetes mellitus for at least 24 months at study entry and are taking at least 2 or 3 preprandial injections per day...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002422-78 Sponsor Protocol Number: 1 Start Date*: 2013-10-14
    Sponsor Name:University of Leicester
    Full Title: Impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes: an open lable, randomised active-comparator trial.
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005057-87 Sponsor Protocol Number: 337HNAS21016 Start Date*: 2022-06-15
    Sponsor Name:Inventiva S.A.
    Full Title: A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of Lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin...
    Medical condition: Type 2 Diabetes (T2DM) with Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005281-30 Sponsor Protocol Number: DUR001-306 Start Date*: 2016-11-03
    Sponsor Name:Allergan Ltd.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk...
    Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10066412 Staphylococcus aureus skin infection LLT
    20.0 10021881 - Infections and infestations 10037633 Pyoderma (skin infection) LLT
    20.1 10021881 - Infections and infestations 10040873 Skin infection aggravated LLT
    20.0 10021881 - Infections and infestations 10040872 Skin infection PT
    20.0 10021881 - Infections and infestations 10040875 Skin infection pyogenic LLT
    20.0 10021881 - Infections and infestations 10040874 Skin infection NOS LLT
    20.1 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:12:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA